Colon Cancer Immunotherapy in India: MSI-H, Pembrolizumab and Nivolumab

Colon cancer immunotherapy in India is an important treatment option for a specific group of patients, particularly those whose tumors are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Unlike chemotherapy, which directly attacks rapidly dividing cells, immunotherapy works by helping the immune system recognize and attack cancer cells. It is not appropriate for every colon cancer patient. The most important factor is the biology of the tumor.

This article is the immunotherapy hub for the colon cluster. The broader pathway is in Colon Cancer Treatment in India. How FOLFOX, CAPOX and FOLFIRI are planned when immunotherapy is not indicated is in Colon Cancer Chemotherapy in India. Stage 4 covers metastatic resectability and conversion therapy. Stage 3 covers adjuvant chemotherapy and the evolving adjuvant immunotherapy discussion. Stage 1 and Stage 2 explain why immunotherapy is not automatically added after surgery. How the operation itself is planned is in Colon Cancer Surgery in India. This is not a rectal-cancer page: radiation has a much larger role when the tumor is rectal. See rectal cancer surgery.

GAF Healthcare planning ranges for immunotherapy are $15,000–$45,000. Precision oncology / molecular testing is $2,000–$7,000. Chemotherapy is $1,500–$8,000+. Targeted therapy is $8,000–$30,000. These are planning ranges, not hospital quotations.

International patients comparing medical oncologists for checkpoint inhibitors commonly start with Delhi NCR immunotherapy, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical-oncology hospitals in Delhi NCR and Mumbai are a typical first filter. Surgical oncologists remain part of the same tumour board if a major response later makes local treatment possible.

Immunotherapy is a type of cancer treatment that helps the immune system recognize and attack cancer cells. Cancer cells can develop mechanisms that allow them to avoid immune-system attack. Immune checkpoint inhibitors interfere with some of these mechanisms. Two important immune checkpoints are PD-1 and CTLA-4. Medicines that block these pathways can release some of the immune system's brakes so T cells can recognize and attack cancer cells more effectively.

A simplified explanation is: the cancer cell uses immune checkpoints to avoid immune attack → a checkpoint inhibitor blocks the immune "brake" → T cells become more active against the cancer → cancer cells may be destroyed or controlled. This is different from conventional chemotherapy, which works through direct cytotoxic effects on cancer cells and other rapidly dividing cells.

Immune checkpoint inhibitors are medicines that block specific proteins involved in immune regulation. The most important ones in colorectal cancer include PD-1 inhibitors (pembrolizumab, nivolumab) and the CTLA-4 inhibitor ipilimumab. Nivolumab and ipilimumab can be combined in selected MSI-H/dMMR metastatic colorectal cancer patients. The FDA approved nivolumab plus ipilimumab in April 2025 for patients aged 12 years and older with unresectable or metastatic MSI-H/dMMR colorectal cancer.

MSI stands for microsatellite instability. Microsatellites are short repeated DNA sequences. When the DNA mismatch-repair system does not work properly, errors can accumulate in these regions. A tumor with a high level of these abnormalities may be classified as MSI-H — microsatellite instability-high.

MMR stands for mismatch repair. The mismatch-repair system identifies and corrects certain errors that occur when DNA is copied. When this system is defective, the tumor may be dMMR — deficient mismatch repair. These tumors often have a high number of mutations and can be more visible to the immune system. That is one reason MSI-H/dMMR tumors can respond particularly well to immune checkpoint inhibitors.

The laboratory method and clinical context should always be considered when interpreting the result. MSI-H and dMMR are closely related but are not exactly the same test.

This test looks for the presence or absence of key mismatch-repair proteins: MLH1, PMS2, MSH2 and MSH6. Loss of one or more proteins can indicate dMMR.

MSI testing evaluates specific DNA markers to determine whether the tumor demonstrates microsatellite instability. Depending on the laboratory, techniques may include PCR-based testing or validated molecular assays. The treating team may use one or both approaches. GAF planning ranges for precision oncology are $2,000–$7,000.

For metastatic colon cancer, current ESMO guidance recommends testing for dMMR/MSI-H specifically to identify patients who may benefit from immune checkpoint inhibition. Knowing the result can change the entire treatment pathway. MSI-H/dMMR — immunotherapy may be a major treatment option. MSS/pMMR — treatment generally follows chemotherapy and targeted-therapy pathways according to RAS, BRAF, tumor location and other factors. Molecular testing should happen before finalizing treatment whenever feasible.

The strongest established role is in unresectable or metastatic MSI-H/dMMR colon cancer. Immunotherapy may also have roles in previously treated MSI-H/dMMR metastatic disease, selected clinical trials, certain locally advanced tumors, selected neoadjuvant settings and emerging biomarker-defined strategies. A patient with Stage 2 colon cancer should not automatically receive the same immunotherapy used for Stage 4 MSI-H disease.

Immunotherapy is not a routine treatment for Stage 1 colon cancer. Most Stage 1 cancers are managed with adequate surgical removal. If the cancer is completely removed and there are no high-risk circumstances requiring additional therapy, immunotherapy is generally unnecessary.

Immunotherapy is not routinely given to every Stage 2 patient. The situation becomes more complex in dMMR/MSI-H tumors, locally advanced disease, clinical-trial settings and selected tumors where neoadjuvant treatment is being investigated. A dMMR/MSI-H result does not automatically mean that every Stage 2 patient should receive immunotherapy.

Stage 3 colon cancer is traditionally treated with surgery plus adjuvant chemotherapy. Immunotherapy is not automatically added to standard postoperative chemotherapy for every Stage 3 patient. The role of immunotherapy in dMMR/MSI-H Stage 3 disease is an active area of clinical development. The ATOMIC study reported in 2025 showed improved disease-free survival when atezolizumab was added to mFOLFOX6 in resected Stage 3 dMMR colon cancer. Because treatment approvals and guidelines continue to evolve, patients with Stage 3 dMMR/MSI-H disease should have their case reviewed against the current guideline and regulatory environment rather than assuming immunotherapy is automatically indicated.

This is where immunotherapy has its most established role. For MSI-H/dMMR metastatic colon cancer, immune checkpoint inhibitors can be used as systemic treatment. Current ESMO guidance recommends nivolumab plus ipilimumab, or pembrolizumab when the combination is not possible, for appropriate first-line patients with dMMR/MSI-H metastatic colorectal cancer. The FDA approved pembrolizumab in 2020 for first-line treatment of unresectable or metastatic MSI-H/dMMR colorectal cancer, and subsequently approved nivolumab plus ipilimumab in 2025. See Stage 4 colon cancer treatment.

Pembrolizumab is a PD-1 immune checkpoint inhibitor and an established option for appropriately selected patients with MSI-H/dMMR unresectable or metastatic colorectal cancer. The KEYNOTE-177 trial compared pembrolizumab with standard chemotherapy-based treatment in previously untreated MSI-H/dMMR metastatic colorectal cancer. The FDA reported a median progression-free survival of 16.5 months with pembrolizumab and 8.2 months with chemotherapy in the initial analysis used for approval. These figures come from a specific clinical-trial population and should not be presented as a guaranteed outcome for an individual patient.

Nivolumab is another PD-1 inhibitor. It can be used for selected MSI-H/dMMR metastatic colorectal cancer patients — alone in selected settings, or in combination with ipilimumab. The FDA converted the accelerated approval for single-agent nivolumab in previously treated MSI-H/dMMR metastatic colorectal cancer to regular approval in 2025.

Nivolumab plus ipilimumab combines PD-1 inhibition with CTLA-4 inhibition. The combination can produce stronger immune activation than a single checkpoint inhibitor in selected patients. The CheckMate-8HW trial demonstrated important benefits from nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer. The 2026 ESMO guideline now recommends nivolumab plus ipilimumab as a first-line option for appropriate dMMR/MSI-H metastatic colorectal cancer patients. A typical regimen begins with combination treatment for a defined number of doses, followed by nivolumab maintenance. The FDA-approved CheckMate-8HW regimen includes nivolumab with low-dose ipilimumab followed by nivolumab maintenance. Patients should not attempt to compare treatment only by the number of infusions.

It is not accurate to say that immunotherapy is universally better than chemotherapy. For MSI-H/dMMR metastatic colon cancer, clinical trials have demonstrated important benefits with checkpoint inhibitors. For MSS/pMMR metastatic colon cancer, standard checkpoint-inhibitor monotherapy generally does not provide the same established benefit. The tumor biomarker determines whether immunotherapy is likely to be useful.

For MSI-H/dMMR metastatic colorectal cancer, current ESMO guidance does not support routinely combining conventional chemotherapy with immune checkpoint inhibitors because available evidence has not established a benefit for such a combination in this setting. That does not mean chemotherapy and immunotherapy can never appear in the same overall treatment journey. A patient may receive immunotherapy → surgery/local treatment → another systemic treatment depending on the clinical course.

Most colon cancers are not MSI-H. Many are MSS/pMMR. These tumors generally do not respond as well to single-agent immune checkpoint inhibition. Routine immunotherapy is not standard for unselected MSS/pMMR metastatic colon cancer. SITC guidance specifically recommends against routine immune checkpoint inhibitor treatment for untreated MSS/pMMR metastatic colorectal cancer outside clinical trials. Combinations that may make immune-resistant tumors more responsive remain an evolving research area.

Tumor mutational burden (TMB) measures the number of mutations in a tumor. Some cancers with very high TMB can respond to immune checkpoint inhibitors. However, TMB should not be treated as a substitute for MSI/MMR testing in colon cancer. Special situations such as POLE/POLD1 alterations may also be relevant in selected tumors. A molecular tumor board can help interpret unusual results.

A BRAF V600E mutation does not automatically rule out immunotherapy. Some BRAF V600E metastatic tumors are also MSI-H/dMMR. Current ESMO guidance states that MSI-H/dMMR tumors with BRAF V600E mutations should still receive first-line immunotherapy because the benefit from immune checkpoint inhibition remains relevant. If the tumor is BRAF V600E + MSS/pMMR, the treatment pathway is different and may involve BRAF-targeted therapy combined with EGFR inhibition and chemotherapy.

Immunotherapy can produce deep and sometimes durable responses in selected MSI-H/dMMR metastatic colon cancer patients. It is not appropriate to promise a cure to every patient. Some patients experience complete response, partial response, stable disease or progressive disease. A small subset can experience very durable disease control.

If a patient has MSI-H/dMMR metastatic colon cancer and limited liver metastases, and immunotherapy produces major tumor shrinkage, the multidisciplinary team may reassess whether liver resection ($10,000–$26,000), ablation or another local treatment is possible. Imaging should be repeated during treatment. A patient who initially appears unresectable may occasionally become a candidate for local treatment after systemic therapy.

The same principle applies to limited lung metastases (surgery, ablation or SBRT) and to peritoneal disease, where selected patients may be assessed for cytoreductive surgery with HIPEC ($18,000–$40,000). The decision should be made by a specialist peritoneal-surface oncology team. See Stage 4 colon cancer treatment.

Immunotherapy is not always given indefinitely. Duration depends on the drug used, clinical response, side effects, treatment guidelines, regulatory labeling, patient preference and disease progression. Current ESMO guidance notes that anti-PD-1 therapy may be continued for up to approximately two years in the metastatic setting, although the optimal duration remains an area of ongoing research. Longer treatment does not automatically mean better treatment.

If the cancer progresses, doctors review whether the tumor truly progressed, whether progression occurred early or after a durable response, previous treatments, molecular profile, whether chemotherapy has previously been used, whether targeted therapy is available, whether local treatment is possible and clinical-trial options. Subsequent treatments may include chemotherapy, targeted therapy, BRAF-directed therapy, HER2-directed therapy, later-line medicines or clinical trials.

Pseudoprogression is an apparent increase in tumor size caused partly by immune-cell infiltration rather than actual cancer growth. It is much less common than true progression but can occur with immunotherapy. Doctors may interpret imaging together with symptoms, laboratory results, timing, overall clinical condition and follow-up imaging. A single scan should not always be interpreted without context.

Monitoring may include CT scans, MRI in selected situations, CEA, blood tests, physical examination and symptom assessment. CEA can be useful when it was elevated at baseline, but CEA alone cannot prove that immunotherapy is working. Some patients with metastatic colon cancer have normal CEA despite significant disease.

Immunotherapy side effects are different from conventional chemotherapy because checkpoint inhibitors activate the immune system. Sometimes the immune system can attack healthy tissues. These are called immune-related adverse events. They can occur during treatment or, in some cases, after treatment has stopped. Common effects include fatigue, rash, itching, diarrhea, reduced appetite, nausea, fever and muscle or joint pain. Many are manageable when identified early.

Immune-related colitis is particularly important in a patient with colon cancer. Symptoms may include frequent diarrhea, abdominal cramps, blood or mucus in stool, urgency and abdominal pain. Severe diarrhea during immunotherapy should not simply be assumed to be "normal chemotherapy diarrhea." NCI identifies colitis and diarrhea as important immune-related complications of checkpoint inhibitors.

Immune-related hepatitis can cause abnormal liver-function tests, jaundice, dark urine, abdominal discomfort and fatigue. Pneumonitis can cause a new cough, breathlessness, chest discomfort or reduced oxygen levels. Checkpoint inhibitors can also affect the thyroid (hypothyroidism, hyperthyroidism, thyroiditis), pituitary and adrenal glands, kidneys, heart and nervous system. Some endocrine side effects may require long-term hormone replacement.

Severe diarrhea with dehydration or blood in stool, new breathlessness or chest pain, jaundice, fainting, confusion, sudden weakness or collapse belongs in a local emergency department — not a delayed WhatsApp message. Patients should never self-medicate with steroids or stop immunotherapy without speaking to the treating team. Treatment of immune-related toxicity may include pausing immunotherapy, close monitoring, corticosteroids, other immunosuppressive treatment in selected severe cases and organ-specific specialists.

Even when a tumor is MSI-H/dMMR, immunotherapy may not be appropriate in every situation. Doctors consider previous organ transplantation, severe autoimmune disease, active uncontrolled infection, previous severe immune-related toxicity, certain medications, organ function, overall health and previous immunotherapy. Having an autoimmune disease does not automatically mean immunotherapy is impossible — the risk depends on the type of disease, activity, current medications, severity and available alternatives.

Patients sometimes worry that steroids automatically cancel out immunotherapy. The situation is more nuanced. Steroids may be medically necessary to treat immune-related adverse events. When appropriately prescribed, they are an important part of managing immunotherapy toxicity. Patients should not avoid necessary steroid treatment because of fear that it will "stop" immunotherapy.

These treatments are different. Immunotherapy works primarily by changing immune-system activity (pembrolizumab, nivolumab, ipilimumab). Targeted therapy ($8,000–$30,000) targets a specific molecular pathway or protein — BRAF-targeted therapy, HER2-targeted therapy, EGFR-targeted therapy or VEGF-directed therapy. A patient can potentially receive different types of treatment during the course of metastatic disease.

Usually, PD-L1 is not the primary biomarker used to select immunotherapy for colon cancer. This is an important distinction from some other cancers. For colorectal cancer, MSI/MMR status is the key established biomarker. A patient should not be told that immunotherapy is appropriate simply because a colon tumor is "PD-L1 positive."

Some MSI-H/dMMR colorectal cancers are associated with Lynch syndrome, an inherited cancer-predisposition condition. MMR/MSI testing can therefore help guide cancer treatment and identify patients who may need genetic evaluation. If the tumor pattern suggests Lynch syndrome, genetic counseling and germline testing may be recommended. This can also have implications for family members.

Checkpoint inhibitors can also be used for selected dMMR/MSI-H rectal cancers, with remarkable responses reported in locally advanced disease. This page focuses on colon cancer. Rectal cancer has different anatomy and treatment pathways and should not simply be treated using the colon cancer algorithm. See rectal cancer surgery.

Neoadjuvant immunotherapy (before surgery) for selected dMMR/MSI-H locally advanced colon cancers is an active area of research. Potential objectives include shrinking the tumor, eliminating microscopic disease, increasing complete response rates and potentially changing the extent of surgery. Adjuvant immunotherapy (after surgery) is more recent. The 2025 ATOMIC results are an important development for resected Stage 3 dMMR colon cancer, but the exact application should follow current guidelines and regulatory approvals. Patients should ask whether the recommended treatment is standard of care, guideline-supported but selected, clinical-trial based or off-label.

There is no single price for colon cancer immunotherapy because treatment depends on the drug, dose, frequency, duration, hospital, manufacturer, patient weight where relevant, insurance or self-pay arrangements, supportive care, laboratory monitoring and imaging. Immunotherapy can be significantly more expensive than conventional chemotherapy, particularly when treatment continues over many months. GAF Healthcare publishes USD planning ranges compiled from partner hospital cost sheets. They are not hospital quotations.

Consider two patients. Patient A has MSI-H metastatic colon cancer treated with pembrolizumab alone. Patient B has MSI-H metastatic colon cancer treated with nivolumab plus ipilimumab followed by nivolumab. The treatment schedules and total medicine costs can be very different. If a patient develops a serious immune-related side effect requiring hospitalization, the total cost can increase substantially.

City pages such as Delhi NCR immunotherapy, Mumbai, Bengaluru, Chennai and Hyderabad use the same national range unless a hospital issues a verified quotation. Ask whether the quotation names the exact immunotherapy drug, dose, number of cycles, treatment interval, drug cost, infusion cost, doctor fees, laboratory costs, imaging and expected follow-up.

Look for a center with medical oncology experienced in colorectal cancer, immunotherapy, targeted therapy, chemotherapy and clinical trials; molecular pathology able to perform MSI testing, MMR immunohistochemistry, RAS, BRAF, HER2 and broader genomic testing; a multidisciplinary team including a medical oncologist, colorectal surgeon, radiologist, pathologist, radiation oncologist and molecular pathologist; and emergency support, because immune-related adverse events can affect the colon, liver, lungs, kidneys, heart and endocrine organs.

International patients should ideally complete molecular testing before travelling if the tests are available locally. Send the colonoscopy report, biopsy, histopathology, CT/MRI/PET scans, CEA, blood tests, previous treatments, MSI/MMR report and molecular reports. Bring the passport, pathology slides and blocks, medication list and discharge summaries. If treatment continues for many months, the patient may discuss transferring subsequent cycles to an oncologist in the home country once the Indian team provides the diagnosis, molecular profile, protocol, dose, infusion schedule, response assessments and side-effect history.

Colon cancer immunotherapy is biomarker-driven, not a treatment automatically given to every patient. MSI-H/dMMR status is the most important established biomarker for checkpoint immunotherapy in colorectal cancer. Pembrolizumab is an established first-line treatment for appropriately selected unresectable or metastatic MSI-H/dMMR colorectal cancer. Nivolumab plus ipilimumab is another important first-line option. MSS/pMMR colon cancer generally does not respond sufficiently to routine checkpoint-inhibitor monotherapy to make it standard treatment. Stage 1 and most Stage 2 colon cancers do not routinely require immunotherapy. The role in Stage 3 dMMR/MSI-H colon cancer is evolving rapidly. Diarrhea during immunotherapy may indicate immune-related colitis and should be reported promptly. A patient-specific quotation should always be obtained before planning travel.

Yes. Immunotherapy is used in appropriately selected colon cancer patients, particularly those with MSI-H/dMMR advanced or metastatic disease. GAF planning ranges for immunotherapy are $15,000–$45,000.

Important immune checkpoint inhibitors include pembrolizumab and nivolumab. Nivolumab can also be combined with ipilimumab in selected MSI-H/dMMR metastatic colorectal cancer patients.

No. The strongest established role is in MSI-H/dMMR disease, particularly advanced or metastatic cancer.

MMR immunohistochemistry and/or MSI testing are the key tests. Broader molecular testing (RAS, BRAF, HER2) still matters for the rest of the treatment pathway. GAF planning ranges for precision oncology are $2,000–$7,000.

MSI-H means microsatellite instability-high. It indicates that the tumor has significant abnormalities in microsatellite DNA sequences and is often associated with defective mismatch repair.

dMMR means deficient mismatch repair. The tumor's DNA mismatch-repair system is not functioning normally.

They are closely related but measured using different testing approaches. Many dMMR tumors are MSI-H, but the terms should not be treated as completely interchangeable.

Routine checkpoint-inhibitor monotherapy is generally not recommended for unselected MSS/pMMR metastatic colon cancer. Clinical trials are investigating ways to make these tumors more responsive.

Not universally. For MSI-H/dMMR metastatic colon cancer, immunotherapy has demonstrated important benefits. For MSS/pMMR disease, chemotherapy and targeted therapies remain central.

Some patients can experience very durable responses, and selected metastatic patients may potentially undergo curative-intent treatment after major response. However, cure cannot be guaranteed.

The duration depends on the drug, treatment setting, response, toxicity and current guidelines. In metastatic disease, treatment may continue for up to approximately two years in some protocols.

Hair loss is generally less characteristic of checkpoint inhibitors than of many chemotherapy regimens, although individual patients can experience skin or hair-related effects.

Yes. Immune-related colitis can cause diarrhea and abdominal symptoms. Significant diarrhea during immunotherapy should be reported promptly. Severe diarrhea with dehydration, blood in stool or collapse belongs in a local emergency department.

Yes. Immune-related hepatitis can occur and is monitored through symptoms and liver-function blood tests.

Yes. Thyroid inflammation and changes in thyroid hormone levels are recognized immune-related effects.

Some immune-related adverse events can persist and require long-term treatment, although many resolve with appropriate management.

The cost depends heavily on the drug, schedule, number of doses, hospital, monitoring and duration. GAF planning ranges for immunotherapy are $15,000–$45,000. A patient-specific quotation is necessary.

Yes. International patients can undergo specialist review, molecular testing, immunotherapy and follow-up at appropriate Indian cancer centers.

In selected patients, treatment may be continued by a local oncology team after coordination with the Indian treating center.

GAF Healthcare coordinates international patients who need a colon cancer immunotherapy opinion in India — after an MSI-H/dMMR result, a question about pembrolizumab versus nivolumab plus ipilimumab, or a Stage 4 plan that may later include local treatment. Share the colonoscopy PDF, the complete pathology report, MSI/MMR result, CT/MRI, CEA, previous treatment records and any RAS/BRAF/HER2 results. A coordinator can introduce a medical oncologist and, when conversion surgery is possible, a surgical oncologist, then help collect an itemised quotation naming the drug, dose, infusion interval and monitoring.

This article is for educational and medical-tourism information only. It does not replace evaluation by a qualified medical oncologist, colorectal surgeon or multidisciplinary cancer team. Immunotherapy should only be prescribed after assessment of the patient's stage, pathology, molecular profile, medical history, contraindications and treatment goals. Patients should not start, stop or change cancer treatment without discussing it with their treating doctor.

1. ESMO — Gastrointestinal cancer guidelines — dMMR/MSI-H as a first decision point; nivolumab plus ipilimumab or pembrolizumab in metastatic colorectal cancer.

2. NCI — Colon Cancer Treatment (PDQ®) — systemic options by stage, including immunotherapy in selected MSI-H/dMMR disease.

3. ASCO — Gastrointestinal cancer guidelines — treatment of metastatic colorectal cancer, including pembrolizumab for MSI-H/dMMR disease.

4. U.S. FDA — pembrolizumab for first-line MSI-H/dMMR colorectal cancer — KEYNOTE-177 median PFS 16.5 vs 8.2 months.

5. U.S. FDA — nivolumab plus ipilimumab for unresectable or metastatic MSI-H/dMMR colorectal cancer — CheckMate-8HW first-line combination approval.

6. 2025 Indian consensus statements for advanced/metastatic colorectal cancer — biomarker-directed first-line choices in Indian practice.

7. NCI — immune checkpoint inhibitors — PD-1 and CTLA-4 blockade.

8. NCI — immunotherapy side effects — colitis, hepatitis, pneumonitis, endocrine and other immune-related adverse events.

9. KEYNOTE-177 — pembrolizumab in MSI-H/dMMR metastatic colorectal cancer — pembrolizumab versus chemotherapy in previously untreated MSI-H/dMMR disease.

10. CheckMate-8HW — nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer — combination checkpoint inhibition versus chemotherapy or nivolumab.

Last reviewed against the cited sources: September 2026.